Esperion Therapeutics (ESPR) Return on Capital Employed (2019 - 2025)
Historic Return on Capital Employed for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 8.44%.
- Esperion Therapeutics' Return on Capital Employed rose 83400.0% to 8.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.44%, marking a year-over-year increase of 83400.0%. This contributed to the annual value of 1.9% for FY2024, which is 41100.0% up from last year.
- Esperion Therapeutics' Return on Capital Employed amounted to 8.44% in Q3 2025, which was up 83400.0% from 0.96% recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Return on Capital Employed registered a high of 8.44% during Q3 2025, and its lowest value of 2.71% during Q4 2023.
- Its 5-year average for Return on Capital Employed is 0.39%, with a median of 0.86% in 2022.
- As far as peak fluctuations go, Esperion Therapeutics' Return on Capital Employed plummeted by -17600bps in 2023, and later soared by 83400bps in 2025.
- Esperion Therapeutics' Return on Capital Employed (Quarter) stood at 0.99% in 2021, then grew by 3bps to 0.95% in 2022, then crashed by -184bps to 2.71% in 2023, then soared by 124bps to 0.66% in 2024, then surged by 1184bps to 8.44% in 2025.
- Its last three reported values are 8.44% in Q3 2025, 0.96% for Q2 2025, and 0.63% during Q1 2025.